We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

158 hedge funds and large institutions have $953M invested in Recursion Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 58 increasing their positions, 43 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more call options, than puts

Call options by funds: $1.04M | Put options by funds: $765K

35% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 43

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

13% more capital invested

Capital invested by funds: $841M → $953M (+$111M)

0.32% more ownership

Funds ownership: 68.76% → 69.08% (+0.32%)

0% more funds holding

Funds holding: 158 → 158 (0)

0% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 26

Holders
158
Holders Change
–
Holders Change %
0%
% of All Funds
2.48%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.09%
New
26
Increased
58
Reduced
43
Closed
26
Calls
$1.04M
Puts
$765K
Net Calls
+$272K
Net Calls Change
+$22K

Top Buyers

1
KA
Kinnevik AB
Sweden
+$19.3M
2
YRHAM
Yong Rong (HK) Asset Management
Hong Kong
+$8.22M
3
AIM
ARK Investment Management
Florida
+$8.13M
4
BlackRock
BlackRock
New York
+$6.91M
5
LIM
Lingotto Investment Management
United Kingdom
+$5.42M

Top Sellers

1
LCM
Laurion Capital Management
New York
-$11.5M
2
Norges Bank
Norges Bank
Norway
-$9.51M
3
State Street
State Street
Massachusetts
-$4.72M
4
HMC
Harvard Management Company
Massachusetts
-$4.39M
5
Millennium Management
Millennium Management
New York
-$4.31M
Name Holding Trade Value Shares
Change 		Change in
Stake
NAMA
26
Nikko Asset Management Americas
New York
$6.25M +$2.35M +335,423 +67%
Balyasny Asset Management
27
Balyasny Asset Management
Illinois
$5.98M +$5.13M +733,334 +1,095%
Dimensional Fund Advisors
28
Dimensional Fund Advisors
Texas
$5.86M +$612K +87,503 +13%
LIM
29
Lingotto Investment Management
United Kingdom
$5.79M +$5.42M +775,077 New
Citadel Advisors
30
Citadel Advisors
Florida
$5.51M +$925K +132,243 +22%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$4.46M +$473K +67,536 +13%
Goldman Sachs
32
Goldman Sachs
New York
$4.31M +$296K +42,318 +8%
Morgan Stanley
33
Morgan Stanley
New York
$2.92M +$916K +130,862 +50%
JP Morgan Chase
34
JP Morgan Chase
New York
$2.8M +$457K +65,347 +21%
PCM
35
Pentwater Capital Management
Florida
$2.73M -$385K -55,000 -13%
Mitsubishi UFJ Trust & Banking
36
Mitsubishi UFJ Trust & Banking
Japan
$2.68M -$62K -8,860 -2%
Renaissance Technologies
37
Renaissance Technologies
New York
$2.62M -$459K -65,561 -16%
Lazard Asset Management
38
Lazard Asset Management
New York
$2.58M -$2.92K -417 -0.1%
Rafferty Asset Management
39
Rafferty Asset Management
New York
$2.39M -$907K -129,569 -29%
AllianceBernstein
40
AllianceBernstein
Tennessee
$2.31M – – –
Swiss National Bank
41
Swiss National Bank
Switzerland
$2.09M +$1.13M +161,900 +138%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$1.93M +$337K +48,097 +23%
Bank of America
43
Bank of America
North Carolina
$1.72M -$2.28M -326,292 -59%
AO
44
Allen Operations
New York
$1.63M – – –
Barclays
45
Barclays
United Kingdom
$1.41M +$3.12K +446 +0.2%
Citigroup
46
Citigroup
New York
$1.32M -$3.57M -510,887 -74%
TRSOTSOK
47
Teachers Retirement System of the State of Kentucky
Kentucky
$1.3M – – –
Ensign Peak Advisors
48
Ensign Peak Advisors
Utah
$1.26M +$1.18M +169,220 New
UBS Group
49
UBS Group
Switzerland
$1.26M -$1.47K -210 -0.1%
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$1.18M +$418K +59,698 +60%
1
2
3 4 5

RXRX Hedge Fund Activity: Q2 2023 in Review

158 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q2 2023, worth a combined $953M — up 13% from $841M a quarter earlier.

Fund positioning in RXRX was balanced in Q2 2023: 26 funds opened new positions, 26 closed out, 58 added to existing stakes and 43 trimmed.

The largest buyer was Kinnevik AB, adding an estimated $19.3M. The largest seller was Laurion Capital Management, cutting an estimated $11.5M.

  • 158 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $953M of Recursion Pharmaceuticals stock for Q2 2023, up 13% quarter-over-quarter.
  • 26 funds opened new Recursion Pharmaceuticals positions in Q2 2023 and 26 closed out, a net change of 0 holders.
  • The largest Recursion Pharmaceuticals buyer in Q2 2023 was Kinnevik AB, an estimated $19.3M added.
  • The largest Recursion Pharmaceuticals seller in Q2 2023 was Laurion Capital Management, an estimated $11.5M sold.

Based on aggregated 13F filings for Q2 2023.